ASND
Ascendis Pharma AS
NASDAQ: ASND · HEALTHCARE · BIOTECHNOLOGY
$238.66
-3.83% today
Updated 2026-06-05
Market cap
$13.32B
P/E ratio
24.72
P/S ratio
15.38x
EPS (TTM)
$8.72
Dividend yield
—
52W range
$161 – $251
Volume
0.7M
WallStSmart proprietary scores
55
out of 100
Grade: C+
Hold
Investment rating
8.0
Growth
A3.0
Quality
D7.0
Profitability
B+5.3
Valuation
C+3/9
Piotroski F-Score
Weak
-2.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$296.40
+24.19%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy13 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 57.30% — above average
+ ROE 103.71% — strong efficiency
+ Revenue growth 144.30% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -2.67 — distress zone
- Negative free cash flow $-15.69M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $51.17M | $266.72M | $363.64M | $691.71M | $865.78M |
| Net income | $-583.19M | $-481.45M | $-378.08M | $-219.03M | $639.69M |
| EPS | — | — | — | — | $8.72 |
| Free cash flow | $-510.19M | $-469.80M | $-307.62M | $43.62M | $-15.69M |
| Profit margin | -1,139.63% | -180.51% | -103.97% | -31.67% | 57.30% |
Peer comparison
Smart narrative
Ascendis Pharma AS trades at $238.66. representing a P/E of 24.72x trailing earnings. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -2.67, it sits in the distress. TTM revenue stands at $865.78M. with profit margins at 57.30%.
Frequently asked questions
What is Ascendis Pharma AS's stock price?
Ascendis Pharma AS (ASND) trades at $238.66, on a P/E of 24.7x and a P/S of 15.4x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Ascendis Pharma AS overvalued?
Ascendis Pharma AS carries a Smart Value Score of 55/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Ascendis Pharma AS (ASND)?
The 12-month analyst consensus target is $296.40, about 24.2% above the current $238.66. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Ascendis Pharma AS's revenue?
Ascendis Pharma AS's trailing twelve-month revenue is $865.78M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Ascendis Pharma AS's Altman Z-Score is -2.67, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio15.38x
ROE103.71%
Beta0.49
50D MA$232.33
200D MA$216.74
Shares out0.06B
Float0.06B
Short ratio—
Avg volume0.7M
Performance
1 week+0.00%
1 month-12.49%
3 months-8.91%
YTD-1.31%
1 year—
3 years—
5 years—